2024-11-21 Helix Biopharma Corp. Announces Issuance of U.S. Patent TSXHBP Press Release - Stockhouse Publishing
| HBP Stock | EUR 1.15 0.00 0.00% |
Slightly above 56% of HELIX BIOPHARMA's investor base is looking to short. The analysis of current outlook of investing in HELIX BIOPHARMA suggests that many traders are alarmed regarding HELIX BIOPHARMA's prospects. HELIX BIOPHARMA's investing sentiment can be driven by a variety of factors including economic data, HELIX BIOPHARMA's earnings reports, geopolitical events, and overall market trends.
HELIX |
2024-11-21 Helix Biopharma Corp. Announces Issuance of U.S. Patent TSXHBP Press Release Stockhouse Publishing
Read at news.google.com
 |
HELIX BIOPHARMA Fundamental Analysis
We analyze HELIX BIOPHARMA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HELIX BIOPHARMA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HELIX BIOPHARMA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
HELIX BIOPHARMA is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
HELIX BIOPHARMA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with HELIX BIOPHARMA stock to make a market-neutral strategy. Peer analysis of HELIX BIOPHARMA could also be used in its relative valuation, which is a method of valuing HELIX BIOPHARMA by comparing valuation metrics with similar companies.
Peers
HELIX BIOPHARMA Related Equities
| 5AM | Hastings Technology | 12.50 | ||||
| N4Q1 | Hemisphere Energy | 0.81 | ||||
| HYEA | Hyster-Yale Materials | 0.65 | ||||
| MEL | Meli Hotels | 0.15 | ||||
| QBI | Q2M Managementberatu | 0.00 | ||||
| RS6 | Reliance Steel | 0.1 | ||||
| DDN | Darden Restaurants | 0.21 | ||||
| 2DG | SIVERS SEMICONDUCTORS | 9.09 |
Additional Tools for HELIX Stock Analysis
When running HELIX BIOPHARMA's price analysis, check to measure HELIX BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HELIX BIOPHARMA is operating at the current time. Most of HELIX BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of HELIX BIOPHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HELIX BIOPHARMA's price. Additionally, you may evaluate how the addition of HELIX BIOPHARMA to your portfolios can decrease your overall portfolio volatility.